Blar i HV - Institutt for naturvitenskapelige helsefag på emneord "Radioimmunotherapy"
Viser treff 1-2 av 2
-
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
(Acta Oncologica;Volume 60, 2021 - Issue 11, Peer reviewed; Journal article, 2021-08-23)Background: The aim of this study was to investigate dosimetry data and clinical variables to predict hematological toxicity in non-Hodgkin lymphoma (NHL) patients treated with [177Lutetium]Lu-liloto-mab satetraxetan. Material ... -
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
(European Journal of Nuclear Medicine and Molecular Imaging;July 2018, Volume 45, Issue 7, Journal article; Peer reviewed, 2018-02-22)Purpose: 177Lu-lilotomab satetraxetan is a novel anti-CD37 antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma (NHL). Four arms with different combinations of pre-dosing and pre-treatment have been ...